How Your Primary Care Practice Left Money on the Table With Pulmonary Hypertension

More than half of U.S. pulmonary hypertension patients are misdiagnosed before receiving the correct diagnosis — and according to a multinational PAH patient survey published in PMC, 71.6% of those patients first walked into a primary care office.

The Internal Medicine practice is ground zero for PH detection. It is also, historically, where PH goes undetected for years.

That is changing. The CorVista System is the first FDA-cleared, machine-learned point-of-care technology capable of indicating the likelihood of elevated mean pulmonary artery pressure — a key marker of pulmonary hypertension — in a 3.5-minute resting test requiring no radiation, no injections, and no referral. According to Medical Product Outsourcing, its PH Add-On earned FDA Breakthrough Device Designation — placing it among fewer than 100 such devices to reach the U.S. market.

With three FDA clearances now in place and a new AMA Category III CPT code effective January 1, 2027, the infrastructure for reimbursable PH screening in the IM office is no longer theoretical. It exists right now.

What You Need to Know About Pulmonary Hypertension Screening in Primary Care: The FDA-Cleared CorVista System

The CorVista System is the first FDA-cleared, machine-learned point-of-care technology capable of flagging elevated mean pulmonary artery pressure — in a 3.5-minute resting test, at the physician's office, with no radiation, no injections, and no referral required.

That matters because the current diagnostic path for PH is, by any clinical standard, broken.

• 51.3% of U.S. PAH patients received at least one misdiagnosis before being correctly identified — most often labeled as COPD, asthma, or heart failure, according to a multinational PAH patient survey published in SAGE Journals
• 71.6% of PAH patients first consulted a primary care physician about their symptoms — placing the Internal Medicine office squarely at the front of the diagnostic failure
• The mean diagnostic delay ranges from 2.5 to 3.9 years and has not meaningfully improved since the NIH Primary PH Registry in the 1980s, per PMC retrospective analysis

The CorVista PH Add-On's IDENTIFY PH validation trial — conducted across more than 11,000 patients — demonstrated 82% sensitivity, 92% specificity, and a negative predictive value exceeding 99%.

A peer-reviewed case series published in JACC: Case Reports (September 2025) made the clinical case plain: CorVista identified Group 2 PH in a patient who had already received multiple negative transthoracic echocardiograms — prompting right heart catheterization that confirmed PH and enabled a diagnosis of HFpEF that prior workups had missed entirely.

In April 2026, Mayo Clinic formalized a prospective research collaboration with CorVista Health to evaluate whether the PH test improves detection, risk stratification, and referral accuracy at scale. That is the validation arc — JACC publication to Mayo partnership — that moves a technology from vendor claim to clinical standard.

The reimbursement infrastructure is now in place. The AMA granted CPT code 1104T on July 1, 2026, covering augmentative AI analysis for CAD, PH, and elevated PCWP — effective January 1, 2027. According to Business Wire, this establishes the formal billing pathway Internal Medicine practices need to generate diagnostic revenue from a tool they can deploy today.

Key Strategies and Best Practices

71.6% of PAH patients first walked into a primary care office with their symptoms — and most left without a diagnosis. According to a multinational real-world survey published in SAGE Journals, the internal medicine office is not a secondary stop on the PH diagnostic journey. It is the first stop. That makes it the highest-leverage intervention point in the entire care pathway.

The clinical literature is now explicit about this. A December 2025 peer-reviewed review in Cureus stated directly that primary and acute care clinicians are positioned to recognize early clues and initiate appropriate evaluation — framing frontline IM physicians not as referral hubs but as active diagnostic participants.

What that looks like operationally:

• Screen before you refer. A 3.5-minute CorVista test at the point of care — no fasting, no radiation, no contrast — rules in or rules out elevated mPAP before a specialist slot opens up.
• Trust the NPV. The IDENTIFY PH trial showed a negative predictive value exceeding 99%. A negative result is clinically actionable. A positive result triggers the referral with evidence behind it.
• Catch what echocardiography misses. According to JACC: Case Reports (September 2025), the CorVista PH test identified Group 2 PH in a patient whose multiple prior transthoracic echocardiograms were all negative — prompting right heart catheterization that confirmed both PH and HFpEF.

On average, three echocardiograms are required to diagnose PAH — spanning more than two years. Your practice does not have to be the bottleneck. It can be the breakthrough.

Common Mistakes to Avoid

Most Internal Medicine practices are not ignoring pulmonary hypertension screening — they simply lack a tool that makes it practical at the point of care. That gap has consequences that show up directly in downstream costs and patient outcomes.

• Relying on echocardiography as the default first screen. The JACC Case Reports publication from Atrium Health Navicent (September 2025) documented patients who had undergone multiple negative transthoracic echocardiograms before PH was identified. Retrospective U.S. healthcare data published in PMC found that nearly one-third of PAH patients waited 10 months or more just to receive their first echocardiogram — and still cycled through a median of 6 specialist visits and 2 hospitalizations before diagnosis. That is not a screening strategy. That is a referral loop.
• Treating dyspnea as a low-priority chief complaint. A December 2025 Cureus peer-reviewed review stated plainly that primary and acute care clinicians are positioned to recognize early PH clues — and are failing to act on them. When exertional dyspnea gets documented and deferred, it often stays deferred.
• Assuming the financial cost of delay falls elsewhere. It does not. According to a pharmacoeconomic study published in PharmacoEconomics – Open (Springer Nature, January 2024), PAH patients with a diagnostic delay exceeding 24 months incurred $5,366 in excess healthcare costs per patient per month compared to those diagnosed within 12 months — driven by ICU stays and 30-day readmissions. That burden cycles back through your panel, your payer relationships, and your quality metrics.

The IM office is the first stop for 71.6% of PAH patients, according to a peer-reviewed real-world survey published in SAGE Journals. Being first without a reliable triage tool is not a neutral position — it is an active miss.

Practical Next Steps

The infrastructure exists. The CPT code is assigned. The Mayo Clinic study is enrolling. The only remaining question is which practices move first — and which ones wait until competitors have already built the billing history.

Here is what a realistic implementation path looks like for an Internal Medicine practice today:

1. Audit your at-risk patient panel now. According to peer-reviewed PubMed research, PH occurs in 60–80% of heart failure patients regardless of ejection fraction type. Your panel almost certainly contains undetected cases.
2. Identify your HFpEF burden. As reported by Patient Care Online, heart failure affects 7.7 million U.S. adults — and HFpEF, roughly half of those cases, remains chronically underdiagnosed. These patients are already on your schedule.
3. Map your CPT code readiness. AMA Category III code 1104T takes effect January 1, 2027. Practices that begin utilization documentation now build the claims history that supports eventual Category I conversion.
4. Evaluate CorVista as a platform, not a single test. Three FDA clearances in under three years — CAD, PH, and PCWP — covering up to 75% of symptomatic cardiovascular disease from one 3.5-minute resting acquisition.

A 2025 systematic review in PharmacoEconomics found monthly PAH treatment costs reaching $14,614 in advanced disease. Early detection is not just clinical — it is the most defensible cost-reduction argument you can make to any payer or administrator.

The infrastructure for earlier pulmonary hypertension diagnosis is no longer theoretical — it exists, it is FDA-cleared, and it has a reimbursement pathway beginning January 1, 2027. What remains is a practice-level decision about who moves first.

According to Hospimedica, the CorVista System delivers a full cardiopulmonary assessment in 3.5 minutes — no radiation, no injections, no fasting. And as JACC: Case Reports (September 2025) confirmed, the test carries a positive likelihood ratio of 10.3, substantially raising post-test probability of PH independent of echocardiography results.

That is not a marginal improvement over current practice. That is a different category of test.

• The diagnostic gap is documented and costly — over two years of average delay, $5,366 in excess monthly costs per delayed patient
• The clinical validation arc is complete — JACC publication, ACC.26 presentation, Mayo Clinic prospective collaboration
• The billing infrastructure is built — AMA Category III CPT code 1104T, effective January 1, 2027
• The patient population is already in your waiting room — 71.6% of PAH patients first present to primary care

The question is not whether your practice has patients with undiagnosed PH. It does. The question is whether your practice is equipped to find them — or whether you are continuing to refer them out after visit five. Learn more about implementing the CorVista System in your practice today.

Frequently Asked Questions

What is the CorVista System and how does it screen for pulmonary hypertension in primary care?

The CorVista System is an FDA-cleared, AI-powered point-of-care device that collects electrical and hemodynamic signals non-invasively over 3.5 minutes to indicate the likelihood of elevated mean pulmonary artery pressure. It requires no radiation, injections, or fasting, and can be administered directly in an internal medicine office without a cardiology referral.

Is there a billing code for pulmonary hypertension screening using the CorVista System?

Yes. The American Medical Association granted CorVista Health a new Category III CPT code (1104T) effective January 1, 2027, covering augmentative AI algorithmic analysis of potential CAD, pulmonary hypertension, and elevated PCWP. This establishes a formal reimbursement pathway for practices adopting the technology.

How accurate is the CorVista PH test?

The IDENTIFY PH clinical validation study demonstrated 82% sensitivity and 92% specificity for identifying elevated mean pulmonary artery pressure, with a negative predictive value exceeding 99%. The test also carries a positive likelihood ratio of 10.3, according to peer-reviewed data published in JACC: Case Reports.

Why is pulmonary hypertension so frequently missed in primary care?

According to a multinational survey published in PMC, more than 51% of U.S. PAH patients received at least one misdiagnosis before a correct diagnosis — most commonly COPD, asthma, or heart failure. The average diagnostic delay ranges from 2.5 to 3.9 years, a figure that has not meaningfully improved since the NIH Primary PH Registry data from the 1980s.

Can the CorVista System detect conditions beyond pulmonary hypertension?

Yes. The CorVista System holds three FDA clearances: coronary artery disease (September 2023), pulmonary hypertension (April 2024), and elevated pulmonary capillary wedge pressure for HFpEF and HFrEF assessment (July 2026). According to Patient Care Online, the platform now supports assessment across conditions accounting for up to 75% of symptomatic cardiovascular disease.